Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

KEY CLINICAL MESSAGE: Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines. ABSTRACT: Fingolimod i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaheb, Saeed, Ghaffary, Elham Moases, Shaygannejad, Vahid, Mirmosayyeb, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126755/
https://www.ncbi.nlm.nih.gov/pubmed/37113637
http://dx.doi.org/10.1002/ccr3.7280
Descripción
Sumario:KEY CLINICAL MESSAGE: Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines. ABSTRACT: Fingolimod is a medication with a potential cure to control multiple sclerosis (MS) relapses. Here we describe a 32‐year‐old woman with relapsing–remitting multiple sclerosis who developed bladder lymphoma induced by long‐term use of Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines.

Ejemplares similares